Pα+ Psychedelic Bulletin #191: Psychedelics at SXSW; Swiss Study Finds No Impact of Psilocybin on Alcohol Use Disorder Post published:March 17, 2025 Post category:Psychedelic Bulletin/Pα+
Behind the Scenes of the “Psychedelic Renaissance” at SXSW 2025 Post published:March 14, 2025 Post category:Analysis/News/Pα+
Inside the World’s Most Active Psychedelic Therapy Site: A Conversation with Sunstone Therapies Post published:March 12, 2025 Post category:Interviews/Pα+
Pα+ Psychedelic Bulletin #190: ‘Europe’s Most Feared Investor’ Teams Up with Musk Associate to Fund Lykos Therapeutics Post published:March 6, 2025 Post category:Psychedelic Bulletin/Pα+
A Rundown of Colorado’s Natural Medicine Program Post published:March 5, 2025 Post category:Analysis/Colorado Natural Medicine Advisory Bulletin/News
Forging a Path to Access: Congressmen Correa and Bergman on the Future of Psychedelics in the U.S. Post published:March 4, 2025 Post category:Interviews
Pα+ Psychedelic Bulletin #189: Psychedelic Philanthropists Weigh In on New Administration; Washington Lawmakers, Experts, Residents Debate Psychedelics Bills; Compass and GH Share Updates Post published:February 28, 2025 Post category:Psychedelic Bulletin/Pα+
Psychedelic Policy Push Continues: Over 60 Bills Introduced Across 22 States Post published:February 27, 2025 Post category:Analysis/News/Pα+
January 2025 Psychedelic Patent Update: Lykos’ New Continuation Applications; Ambio Files on Ibogaine & Magnesium Post published:February 25, 2025 Post category:Psychedelic Patent Analysis/Pα+
A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at The Harvard Divinity School Post published:February 24, 2025 Post category:News